Ivan De Weber's journey from a Ph.D. in aging genetics to the forefront of cheminformatics is nothing short of inspirational. By joining forces with his childhood friend, a quantum information expert, Ivan has created a powerhouse team that's redefining the limits of what's possible in drug discovery.
Harnessing AI for Unprecedented Accuracy
Cortex Discovery's neural networks aren't just impressive – they're revolutionary. With the ability to process 750 million data points and predict molecular properties with astounding accuracy, this AI is outperforming traditional methods in ways we never thought possible.
Proof That Demands Attention
Cortex Discovery has the receipts:
1. A COVID-19 study where 5 out of 6 predicted compounds were effective.
2. Successful collaborations with Stanford University and a Norwegian company, yielding groundbreaking results.
3. Predictions as accurate as experimental reproducibility itself.
These aren't just wins; they're paradigm shifts.
The Numbers Don't Lie
Cortex Discovery's method is 20 times more cost-effective than traditional approaches. It screens 10 times fewer compounds but yields 5 times more hits. This isn't just an improvement; it's a complete overhaul of the drug discovery process.
The Future is Here, and It's Cortex Discovery
Ivan and his team aren't content with just predicting molecular properties. They're venturing into generative AI, exploring trillions of potential compounds, and developing a docking system that promises to outperform everything currently on the market.
A Call to Action
If you're in the longevity field or working with small molecules, you can't afford to ignore Cortex Discovery. The opportunity to accelerate your research by months, if not years, is at your fingertips. Don't let your competitors get there first.
The Time to Act is Now
Ivan de Weber and Cortex Discovery are offering more than just a service – they're offering a partnership in shaping the future of medicine. This is your chance to be part of a revolution that could change the face of drug discovery forever.
The future of drug discovery is here – are you ready to be part of it?
If you're interest by AI-driven drug discovery 👇👇👇
ITW Dr. Ivan De Weber, PhD - Cofounder-CEO at Cortex Discovery
Exciting news! 🚀 Join us for the next episode of our LinkedIn Live podcast featuring Dr. Ivan De Weber, PhD Weber, co-founder and CEO of Cortex Discovery, a groundbreaking startup revolutionizing drug discovery through AI!
🔬 From Academia to AI-Powered Drug Discovery
Dr. de Weber's journey is nothing short of inspiring. We'll explore his transition from cellular biology and pharmaceutical bioinformatics to founding a company at the cutting edge of AI-driven drug discovery. Learn how his lifelong quest for longevity research led to the creation of Cortex Discovery.
🧠 Unveiling Cortex Discovery's Innovative Approach
Discover how Cortex Discovery is disrupting preclinical drug discovery across all therapeutic areas with their proprietary AI models. We'll delve into:
• Their foundation model for drug property predictions
• The vast database of 750 million data points powering their deep learning system
• Recent breakthroughs, including the first AI-discovered compound proven to extend lifespan in a whole organism
💼 Business Insights and Future Outlook
Get an insider's perspective on:
• Cortex Discovery's unique business model and collaboration opportunities
• Challenges faced in the AI-driven drug discovery landscape
• The company's vision for the future of longevity research and pharmaceutical development
This episode is a must-watch for:
• Biotech and pharmaceutical executives
• Investors in the life sciences sector
• Academic researchers in pharmaceutical chemistry, longevity biology, and clinical medicine
• Anyone interested in the intersection of AI and drug discovery
Don't miss this opportunity to gain valuable insights into the future of AI-powered drug discovery and longevity research. Tune in to our LinkedIn Live podcast and be part of the conversation shaping the future of medicine!